Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee, S Oza, A Birrer, M Hamilton, E Hasan, Jurjees Leary, A Moore, K Mackowiak-Matejczyk, B Pikiel, J Ray-Coquard, I
Banerjee, S
Oza, A
Birrer, M
Hamilton, E
Hasan, Jurjees
Leary, A
Moore, K
Mackowiak-Matejczyk, B
Pikiel, J
Ray-Coquard, I
Citations
Altmetric:
Abstract
Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent anti-mitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. This study is the first to compare an antibody-drug-conjugate (ADC) to standard-of-care in ovarian cancer (OC) patients.
Description
Date
2018-02-01
Publisher
Collections
Keywords
Type
Article
Citation
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. 2018, Ann Oncol